Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Posts Flat Revenues, Narrowed Loss in Fiscal Q1; Sheds No Light on BACcelr8r Availability

NEW YORK (GenomeWeb News) — Accelr8 Technology yesterday said fiscal first-quarter revenues were unchanged though net loss decreased 30 percent.  
 
Total receipts for the three months ended Oct. 31 were flat at $86,000.
 
Accelr8 said net losses declined to $539,000 from $772,000 in the year-ago period.
 
The company attributed the decline to reduced research expenses for its BACcelr8r bacterial-analysis system, which is being prepared for clinical trials.
 
The company had maintained since the fall of 2004 that it would begin marketing the test in its fiscal 2006, which ended July 31, but in June President David Howson admitted that was not going to happen.
 
The company did not specify yesterday when it expects the test to be available for sale.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.